Drugs / TransCon PEG treprostinil
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02149095 | Jul → Nov 2014 | pulmonary arterial hypertension | United Therapeutics | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TransCon PEG treprostinil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02149095 ↗ |
| Route | Subcutaneous | “subcutaneous injection” NCT02149095 ↗ |